{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:55:20Z","timestamp":1784609720668,"version":"3.55.0"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,9,18]],"date-time":"2009-09-18T00:00:00Z","timestamp":1253232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The highest approved dose of deferasirox is currently 30\u2003mg\/kg per d in many countries; however, some patients require escalation above 30\u2003mg\/kg per d to achieve their therapeutic goals. This retrospective analysis investigated the efficacy (based on change in serum ferritin levels) and safety of deferasirox &gt;30\u2003mg\/kg per d in adult and paediatric patients with transfusion\u2010dependent anaemias, including \u03b2\u2010thalassaemia, sickle cell disease and the myelodysplastic syndromes. In total, 264 patients pooled from four clinical trials received doses of &gt;30\u2003mg\/kg per d; median exposure to deferasirox &gt;30\u2003mg\/kg per d was 36\u2003weeks. In the overall population there was a statistically significant median decrease in serum ferritin of 440\u2003\u03bcg\/l (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030\u00b70001) from pre\u2010dose\u2010escalation to the time\u2010of\u2010analysis; significant decreases were also observed in adult and paediatric patients, as well as \u03b2\u2010thalassaemia patients. The adverse event profile in patients who received deferasirox doses of &gt;30\u2003mg\/kg per d was consistent with previously published data. There was no worsening of renal or liver function following dose escalation. Deferasirox &gt;30\u2003mg\/kg per d effectively reduced iron burden to levels lower than those achieved prior to dose escalation in patients with transfusion\u2010dependent anaemias. This has important implications for patients who are heavily transfused and may require higher doses to reduce body iron burden.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2009.07908.x","type":"journal-article","created":{"date-parts":[[2009,9,18]],"date-time":"2009-09-18T14:07:37Z","timestamp":1253282857000},"page":"752-759","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Efficacy and safety of deferasirox doses of &gt;30\u2003mg\/kg per d in patients with transfusion\u2010dependent anaemia and iron overload"],"prefix":"10.1111","volume":"147","author":[{"given":"Ali","family":"Taher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D.","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Vichinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Galanello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Lawniczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.39.3.253"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109306"},{"key":"e_1_2_7_5_1","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once\u2010daily oral chelating agent, in paediatric patients with \u03b2\u2010thalassaemia major","volume":"91","author":"Galanello R.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13309-0"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310903"},{"key":"e_1_2_7_9_1","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once\u2010daily, orally\u2010administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga A.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2778.2778","article-title":"Impact of dose adjustments on serum ferritin (SF) levels during long\u2010term treatment with once\u2010daily, oral deferasirox (Exjade\u00ae, ICL670)","volume":"110","author":"Porter J.B.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00985.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01228.x"},{"key":"e_1_2_7_13_1","unstructured":"Thalassaemia International Federation. (2008)Guidelines for the clinical management of thalassaemia 2nd Revised Edition. Available at:http:\/\/www.thalassaemia.org.cy\/pdf\/Guidelines_2nd_revised_edition_EN.pdf. Accessed on 9 Sept 2009."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06455.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2009.07908.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2009.07908.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:11:46Z","timestamp":1697443906000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2009.07908.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,6]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1365-2141.2009.07908.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07908.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,6]]},"assertion":[{"value":"2009-11-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}